Literature DB >> 12075738

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.

D Cardinale1, M T Sandri, A Martinoni, E Borghini, M Civelli, G Lamantia, S Cinieri, G Martinelli, C Fiorentini, C M Cipolla.   

Abstract

BACKGROUND: High-dose chemotherapy (HDC) has been widely utilized in high-risk breast cancer, but it may induce cardiac toxicity. Cardiac dysfunction may become evident weeks or months after HDC and, to date, no early markers of myocardial injury that are able to predict late ventricular impairment are available. We investigated the role of plasma troponin I (TnI) in this setting. PATIENTS AND METHODS: We measured TnI plasma concentration after HDC in 211 high-risk breast cancer women (46 +/- 11 years, mean +/- SD). According to TnI value (< 0.5 or > or = 0.5 ng/ml), patients were allocated into a troponin positive (TnI+; n = 70) and a troponin negative (TnI-; n = 141) group. All patients underwent left ventricular ejection fraction (LVEF, Echo) examination during the following 12 months.
RESULTS: LVEF progressively decreased in the TnI+ group but not in the TnI- group. In TnI+ patients a close relationship between the TnI increase, as well as the number of positive TnI assays, and the maximal LVEF decrement, was found (r = -0.92, P < 0.0001 and r = -0.93, P < 0.0001, respectively).
CONCLUSIONS: In our population, the elevation of TnI soon after HDC accurately predicts the development of future LVEF depression. In this setting, TnI can be considered a sensitive and reliable marker of myocardial damage with relevant clinical and prognostic implications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075738     DOI: 10.1093/annonc/mdf170

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  77 in total

Review 1.  Early detection of chemotherapy-related left ventricular dysfunction.

Authors:  Jeanne M DeCara
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

2.  Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Carlo Maria Cipolla
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-12

3.  Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation.

Authors:  Julian Puppe; Deborah van Ooyen; Jeanne Neise; Fabinshy Thangarajah; Christian Eichler; Stefan Krämer; Roman Pfister; Peter Mallmann; Marina Wirtz; Guido Michels
Journal:  Breast Care (Basel)       Date:  2017-01-18       Impact factor: 2.860

Review 4.  Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.

Authors:  Gina Biasillo; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

Review 5.  Cardio-oncology: the Nuclear Option.

Authors:  Jorge A Alvarez; Raymond R Russell
Journal:  Curr Cardiol Rep       Date:  2017-04       Impact factor: 2.931

6.  Cardiac complications of chemotherapy: role of biomarkers.

Authors:  Alessandro Colombo; Maria T Sandri; Michela Salvatici; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

Review 7.  The breast cancer patient in the cardioncology unit.

Authors:  Daniela Cardinale; Vincenzo Caruso; Carlo M Cipolla
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 8.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

9.  Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.

Authors:  John D Groarke; Toni K Choueiri; David Slosky; Susan Cheng; Javid Moslehi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

10.  'Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population': a feasibility study PEACH trial: prescribed exercise after chemotherapy.

Authors:  Julie M Walsh; Juliette Hussey; Emer Guinan; Dearbhaile O' Donnell
Journal:  BMC Cancer       Date:  2010-02-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.